In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36063554.
- Also identified by DOI 10.7326/J22-0067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lv J, Wong MG, Hladunewich MA, et al. <b>Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial.</b> JAMA. 2022;327:1888-98. 35579642.
Medical subject headings
- Glomerulonephritis, IGA